debt_leverage_profile
0.86x Total Debt / Equity (Moderate leverage)
High
SEC-XBRL
interest_rate_sensitivity
Low sensitivity; minimal long-term debt, small credit facility ~$2M; 200bps rate rise adds <$40K annual interest cost
Inferred
Agent_Inference
geopolitical_supply_exposure
Low intensity; China and India supply >60% of global API inputs, creating concentration risk.
Medium
GICS-commodity-overlay-v1
supply_chain_dependency
Hawaii-based cultivation limits geographic risk, but CO2 supply logistics and imported processing chemicals are key chokepoints
Inferred
Agent_Inference
international_expansion_readiness
Export revenues (~30-40% of sales) exposed to JPY and EUR softness; no active hedging program disclosed; material but manageable devaluation risk
Inferred
Agent_Inference
geographic_footprint
Primary markets: Japan, Europe, US; JPY depreciation (~15% 2022-2023) and EUR softness directly compress export revenue realizations
Inferred
Agent_Inference
commodity_exposure_profile
Low intensity; commodities: Active Pharmaceutical Ingredients, Rare Earth Elements, Natural Gas (energy), Plastics/Resins, Ethanol, Packaging Materials; geopolitical: China and India supply >60% of global API inputs, creating concentration risk.
Medium
GICS-commodity-overlay-v1
vendor_lock_dependency_score
Single-site Hawaii cultivation facility creates near-total operational dependency; no alternative production site; substitution risk is high
Inferred
Agent_Inference
business_model_type_primary
Minimal cloud infrastructure dependency; operations are physical biotech/agriculture; cloud termination would affect ERP/admin, not core production
Inferred
Agent_Inference
business_model_type_secondary
Physical product manufacturer and distributor; digital systems are ancillary; 30-day cloud termination would cause administrative disruption only
Inferred
Agent_Inference
switching_cost_profile
Low API coupling risk; company operates physical manufacturing with standard ERP tools; no proprietary platform dependencies identified
Inferred
Agent_Inference
howey_test_risk_index
Fails Howey Test; revenue from physical product sales (spirulina, astaxanthin); no investment contract structure; near-zero securities classification risk
Inferred
Agent_Inference
regulatory_burden_tier
Very High
Medium
GICS-regulatory-overlay-v1
data_sovereignty_risk
Limited GDPR/CCPA exposure; B2B and wholesale model reduces consumer data collection; basic e-commerce compliance required but low complexity
Inferred
Agent_Inference
antitrust_exposure_flag
Minimal antitrust risk; operates in fragmented nutraceutical market with multiple competitors; market share insufficient to attract regulatory scrutiny
Inferred
Agent_Inference
regulatory_exposure_profile
Very High burden; regimes: FDA, CMS, HHS, HIPAA, EMA, OIG; Drug pricing legislation and approval delays directly compress revenue visibility.
Medium
GICS-regulatory-overlay-v1
revenue_model_type
~85-90% transactional product sales; small recurring component via bulk/contract supply agreements; limited subscription revenue
Inferred
Agent_Inference
monetization_vector
Primarily wholesale bulk ingredient sales and branded retail product sales; direct-to-consumer e-commerce is secondary monetization channel
Inferred
Agent_Inference
pricing_architecture
Cost-plus pricing vulnerable to energy and labor cost inflation in Hawaii; premium natural positioning provides modest buffer but limited pricing power
Inferred
Agent_Inference
pricing_power_rating
3/10; commodity-adjacent nutraceutical ingredients face price competition from low-cost Asian producers; brand premium partially offsets but constrained
Inferred
Agent_Inference
target_gross_margin_bracket
28.4% Gross Margin (Moderate (20-40%))
High
SEC-XBRL
churn_vulnerability_index
No significant free-rider problem; physical product model requires purchase; wholesale customer churn risk moderate if competitors undercut on price
Inferred
Agent_Inference
headcount_cost_structure
Revenue growth is largely headcount-linear due to physical cultivation and processing; doubling revenue requires near-proportional production staff increase
Inferred
Agent_Inference
marginal_cost_of_growth
High marginal cost; capacity expansion requires capital-intensive pond construction and equipment; no software-like scalability; COGS-heavy model
Inferred
Agent_Inference
franchise_compliance_risk
Not applicable; no franchise network; direct manufacturing and distribution model only
Inferred
Agent_Inference
customer_acquisition_metric
At 10x scale, CAC would rise sharply; wholesale channel economics depend on distributor relationships; Hawaii production constraints limit scalable unit economics
Inferred
Agent_Inference
network_effect_present
No network effects present; physical nutraceutical product with no platform dynamics; user growth does not enhance product value for other users
Inferred
Agent_Inference
asset_efficiency_ratio
-13.6% Return on Assets (Negative equity)
High
SEC-XBRL
recession_resistance_tier
Tier 3 (moderate vulnerability); health supplement demand softens in downturns as consumers trade down to cheaper alternatives or eliminate discretionary spend
Inferred
Agent_Inference
customer_segment_primary
Health food distributors, nutraceutical manufacturers, and bulk ingredient buyers representing estimated 60-70% of revenue
Inferred
Agent_Inference
customer_segment_secondary
Direct-to-consumer retail customers purchasing branded Nutrex Hawaii spirulina and BioAstin astaxanthin supplements online and in natural food stores
Inferred
Agent_Inference
characteristic_occupations
["11-0000 Management Occupations", "13-0000 Business and Financial Operations Occupations", "15-0000 Computer and Mathematical Occupations", "19-0000 Life, Physical, and Social Science Occupations", "21-0000 Community and Social Service Occupations", "23-0000 Legal Occupations", "29-0000 Healthcare Practitioners and Technical Occupations", "31-0000 Healthcare Support Occupations", "41-0000 Sales and Related Occupations", "43-0000 Office and Administrative Support Occupations", "51-0000 Production Occupations"]
High
SOC-2018/GICS-overlay
agent_automatable_labor_share
0.32 (HIL — ~32% of characteristic roles agent-automatable)
Medium
SOC-2018 + agentic-exposure-v1
capital_expenditure_profile
null
Inferred
Agent_Inference
sec_cik
0000768408
High
SEC-EDGAR
ticker
CYAN
High
SEC-EDGAR